Suppr超能文献

儿童中枢神经系统自身免疫性神经疾病

Childhood autoimmune neurologic diseases of the central nervous system.

作者信息

Jones Charlotte T

机构信息

Department of Pediatrics, Joan C. Edwards School of Medicine, Marshall University, 1600 Medical Center Drive, Suite 3500, Huntington, WA 25701, USA.

出版信息

Neurol Clin. 2003 Nov;21(4):745-64. doi: 10.1016/s0733-8619(03)00007-0.

Abstract

An autoimmune mechanism for ADEM and MS can be supported by the similar patterns of pathologic changes seen in both diseases with the animal model EAE induced by inoculating animals with nervous tissue and the occurrence of ADEM in patients exposed to nervous tissue during vaccination. Whereas there are no universally agreed-upon criteria for the diagnosis of ADEM, a combination of prodromal illness or preceding vaccination, MRI signs of demyelination, and an acute presentation of neurologic symptoms are the triad most commonly looked for in making the diagnosis of ADEM. An ever-increasing number of infections and vaccinations (nonspecific URIs being most common) has been associated with ADEM. Fever and encephalopathy are seen frequently at presentation. Seizures also are common, as are cranial nerve abnormalities and motor symptoms. A mild pleocytosis or protein elevation is found in the majority of patients with ADEM. Intrathecal IgG synthesis and oligoclonal bands are relatively infrequent but should not be considered inconsistent with the diagnosis of ADEM. White matter changes on T2 in a bilateral although asymmetric distribution with relative sparing of the periventricular region with or without deep gray matter involvement is consistent and to some a requirement for the diagnosis. Low-dose steroids have no beneficial effect in the treatment of ADEM and may be contraindicated. High-dose steroids may have a beneficial effect, particularly in more prolonged illnesses, although the evidence is primarily anecdotal. If steroids are used to improve morbidity, 30 mg/kg/d of methylprednisolone for three to five days is the dose with a six-week taper to reduce the risk of recurrence. The prodromal infection may be a major factor in the ultimate mortality and morbidity of the disease. The current mortality of ADEM is quite low. Whether or not this is an effect of different triggering agents or changes in medical care cannot be determined. In larger series of patients with ADEM, 10% to 20% of children experience some sort of recurrence with the majority occurring in the initial one to two months after the first event. This is sometimes associated with steroid withdrawal. A second group of children have a late second recurrence that clinically may not be MS but a recurrence of ADEM, although longer follow-up may change that assessment. Two months should be allowed before a second relapse is considered a manifestation of MS, whereas a second attack also may occur years after an initial attack of ADEM and still be consistent with ADEM recurrence. MS does occur during childhood, with the youngest children at the least risk, and risk increasing with age. The criteria of Poser et al can be used to diagnose MS in childhood [40]. The presentation of MS in childhood is most often sensory, motor, and brainstem signs and symptoms. A relapsing-remitting course is most common with a first relapse occurring in the year after presentation. MRI findings in MS typically show periventricular changes. Oligoclonal bands and CSF IgG synthesis are found in the majority. Treatments of childhood MS have not been studied adequately, but, when treatments studied in adults are used in children, they are well tolerated. Efficacy has not been shown. The long-term outcome of MS in childhood can be either severe or benign with no clear consensus that childhood MS is either a less or more severe disease than the adult form. ATM and ON treatments and outcomes are particularly difficult to evaluate because of the heterogeneity of populations included in case series and the small numbers reported. Steroids are used with anecdotal reports of their superiority to nontreatment. Outcome in ATM often can be poor, whereas in ON it rarely is. A multinational collaborative effort to study and collect the large numbers necessary to address the important questions in these childhood autoimmune disorders would be of great benefit and the only way likely to demonstrate good evidenced-based medicine practiced in this field.

摘要

急性播散性脑脊髓炎(ADEM)和多发性硬化症(MS)的自身免疫机制可以通过两种疾病中出现的相似病理变化模式得到支持,这些病理变化模式在接种神经组织诱导的动物模型实验性自身免疫性脑脊髓炎(EAE)中可见,并且在接种疫苗期间接触神经组织的患者中出现ADEM。虽然目前尚无普遍公认的ADEM诊断标准,但前驱疾病或先前接种疫苗、脱髓鞘的MRI征象以及神经系统症状的急性表现这三者结合是诊断ADEM时最常寻找的三联征。越来越多的感染和疫苗接种(最常见的是非特异性上呼吸道感染)与ADEM相关。发热和脑病在发病时很常见。癫痫发作也很常见,颅神经异常和运动症状同样如此。大多数ADEM患者存在轻度脑脊液细胞数增多或蛋白升高。鞘内IgG合成和寡克隆带相对少见,但不应被视为与ADEM诊断不符。T2加权像上双侧白质改变,尽管分布不对称,脑室周围区域相对 spared,无论有无深部灰质受累,都是一致的,并且在某些情况下是诊断的必要条件。低剂量类固醇对ADEM治疗无有益作用,甚至可能是禁忌的。高剂量类固醇可能有有益作用,特别是在病程较长的疾病中,尽管证据主要是轶事性的。如果使用类固醇来改善病情,甲基泼尼松龙剂量为30mg/kg/d,连用三至五天,然后六周逐渐减量以降低复发风险。前驱感染可能是该疾病最终死亡率和发病率的主要因素。目前ADEM的死亡率相当低。这是否是不同触发因素或医疗护理变化的结果尚无法确定。在较大系列的ADEM患者中,10%至20%的儿童会出现某种复发,大多数复发发生在首次发病后的最初一至两个月内。这有时与类固醇撤药有关。另一组儿童会出现较晚的第二次复发,临床上可能不是MS而是ADEM复发,尽管更长时间的随访可能会改变这种评估。在第二次复发被认为是MS表现之前应等待两个月,而第二次发作也可能发生在ADEM首次发作数年之后,并且仍然符合ADEM复发。MS确实会在儿童期发生,年龄最小的儿童风险最低,风险随年龄增加。波泽等人的标准可用于诊断儿童期MS。儿童期MS的表现最常见的是感觉、运动和脑干体征及症状。复发缓解型病程最常见,首次复发发生在发病后一年内。MS的MRI表现通常显示脑室周围改变。大多数患者可发现寡克隆带和脑脊液IgG合成。儿童期MS的治疗尚未得到充分研究,但是,当将在成人中研究的治疗方法用于儿童时,耐受性良好。尚未显示出疗效。由于病例系列中纳入人群的异质性以及报告数量较少,儿童期急性横贯性脊髓炎(ATM)和视神经炎(ON)的治疗及结果特别难以评估。使用类固醇有一些轶事性报告称其优于不治疗。ATM的结果通常较差,而ON的结果很少如此。开展一项多国合作努力来研究和收集解决这些儿童自身免疫性疾病中重要问题所需的大量数据将大有裨益,并且这是在该领域实践良好循证医学的唯一可能途径。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验